NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Tony Mok(Chinese University of Hong Kong), Nobuyuki Yamamoto(Wakayama Medical University), Vladimir Moiseyenko(Institute of Oncology NN Petrov), Ihor Vynnychenko(Sumy State University), Rajiv Raja(AstraZeneca (United States)), Claudio Martín(Instituto Alexander Fleming), Yvonne Summers(The Christie NHS Foundation Trust), Mustafa Erman(Hacettepe University Hospital), Ying Cheng(Jilin Province Tumor Hospital), Alona Zer(Rambam Health Care Campus), Jill Walker(AstraZeneca (United Kingdom)), Vikram K. Chand(Research & Development Institute), Sung Yong Lee(Korea University), Kirsha Naicker(AstraZeneca (United Kingdom)), Helen Mann(AstraZeneca (United Kingdom)), Naiyer A. Rizvi(Synthego (United States)), Maciej Bryl, Konstantinos Syrigos(National and Kapodistrian University of Athens), Constanta Timcheva, Peter Schmid(Queen Mary University of London), Urban Scheuring(AstraZeneca (United Kingdom))
Cited by 72
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k